GRFS
Grifols SA
$7.64
+2.00%
$5.3B
No data for this timeframe.
Vol
Market Cap$5.3B
Cap SizeMid Cap
Inst. Holders50 funds
Inst. Value$711.1M
Inst. Activity11 buys / 8 sells
Press Releases1
Recent Activity
Inst.
BANK OF MONTREAL /CAN/ — TRIM
2,506,278 shares ($20.1M)
Inst.
HARRIS ASSOCIATES L P — TRIM
1,821,667 shares ($14.6M)
May 20, 2026
clinical_trial_readout
T-90d Trial Readout: Alpha-1 MP (Phase 3)
Trial: Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in
Mar 17, 2026
Press
Grifols announced proof-of-concept data from its Chronos-PD program, showing biological changes in Parkinson’s disease c
Impact 7/10
Price Targets
Historical data — last covering-analyst action Dec 2025. No current recommendation available.
$10.87 (Dec 2025)
Current $7.64
Low $10.00
Median $10.87
High $11.73
2 analysts
$10.00
$11.73
Analyst Ratings
5Strong Buy
9Buy
5Hold
2Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Dec 8, 2025 | JP Morgan | MAINTAIN | Neutral → Neutral |
| Jun 17, 2025 | JP Morgan | MAINTAIN | Neutral → Neutral |
| Mar 12, 2024 | Deutsche Bank | DOWNGRADE | Hold → Sell |
| Dec 5, 2023 | JP Morgan | MAINTAIN | Neutral → Neutral |
| Nov 5, 2021 | Deutsche Bank | DOWNGRADE | Buy → Hold |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $0.28 ▲ +2.2% | $0.28 — $0.28 | 24% YoY | 1 |
| Next Q | $0.29 ▼ -3.4% | $0.29 — $0.29 | 1 | |
| Current FY | $1.06 ▼ -9.2% | $1.06 — $1.06 | 23% YoY | 1 |
| Next FY | $1.44 ▼ -0.8% | $1.34 — $1.55 | 36% YoY | 2 |
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BRANDES INVESTMENT PARTNERS, LP | $291.4M | — |
| Capital World Investors | $183.9M | — |
| BANK OF AMERICA CORP | $34.7M | ADD |
| JANUS HENDERSON GROUP PLC | $26.4M | — |
| MORGAN STANLEY | $22.9M | ADD |
50 institutional holders with $711.1M total value (88,671,071 shares) as of 2026-Q1. Top holders: BRANDES, Capital, BANK. Net buying activity: 11 institutions added/increased vs 8 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BRANDES INVESTMENT PARTNERS, LP | 36,333,714 | $291.4M | 41.0% | — |
| 2 | Capital World Investors | 22,924,990 | $183.9M | 25.9% | — |
| 3 | BANK OF AMERICA CORP /DE/ | 4,327,413 | $34.7M | 4.9% | ADD +32.3% |
| 4 | JANUS HENDERSON GROUP PLC | 3,290,089 | $26.4M | 3.7% | — |
| 5 | MORGAN STANLEY | 2,857,956 | $22.9M | 3.2% | ADD +56.4% |
| 6 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 2,723,385 | $21.8M | 3.1% | DOUBLED +383.7% |
| 7 | BANK OF MONTREAL /CAN/ | 2,506,278 | $20.1M | 2.8% | TRIM -43.0% |
| 8 | BARCLAYS PLC | 2,104,594 | $16.9M | 2.4% | DOUBLED +722.5% |
| 9 | HARRIS ASSOCIATES L P | 1,821,667 | $14.6M | 2.1% | TRIM -32.3% |
| 10 | BlackRock, Inc. | 1,511,621 | $12.1M | 1.7% | — |
| 11 | GOLDMAN SACHS GROUP INC | 1,325,965 | $10.6M | 1.5% | — |
| 12 | SEI INVESTMENTS CO | 1,251,579 | $10.0M | 1.4% | TRIM -31.3% |
| 13 | WELLS FARGO & COMPANY/MN | 1,053,433 | $8.4M | 1.2% | — |
| 14 | ROYAL BANK OF CANADA | 785,703 | $6.3M | 0.9% | — |
| 15 | Verition Fund Management LLC | 701,611 | $5.6M | 0.8% | — |
| 16 | STATE STREET CORP | 646,207 | $5.2M | 0.7% | ADD +67.6% |
| 17 | ENVESTNET ASSET MANAGEMENT INC | 467,028 | $3.7M | 0.5% | ADD +34.7% |
| 18 | Hudson Bay Capital Management LP | 287,874 | $2.3M | 0.3% | — |
| 19 | STIFEL FINANCIAL CORP | 263,243 | $2.1M | 0.3% | ADD +28.3% |
| 20 | Capital International, Inc./CA/ | 190,360 | $1.5M | 0.2% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| BANK OF MONTREAL /CAN/ | TRIM | 4,394,750 | 2,506,278 | -43.0% | $20.1M | 2026-Q1 |
| HARRIS ASSOCIATES L P | TRIM | 2,689,100 | 1,821,667 | -32.3% | $14.6M | 2026-Q1 |
| ENVESTNET ASSET MANAGEMENT INC | ADD | 346,605 | 467,028 | +34.7% | $3.7M | 2026-Q1 |
| STIFEL FINANCIAL CORP | ADD | 205,219 | 263,243 | +28.3% | $2.1M | 2026-Q1 |
| Mariner, LLC | ADD | 97,327 | 125,151 | +28.6% | $1.0M | 2026-Q1 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 62,908 | 119,303 | +89.6% | $956.8K | 2026-Q1 |
| FMR LLC | TRIM | 93,500 | 68,556 | -26.7% | $549.8K | 2026-Q1 |
| Atria Investments, Inc | ADD | 51,924 | 66,159 | +27.4% | $530.6K | 2026-Q1 |
| Orion Porfolio Solutions, LLC | ADD | 38,836 | 59,584 | +53.4% | $477.9K | 2026-Q1 |
| Point72 Asset Management, L.P. | NEAR_EXIT | 277,406 | 51,357 | -81.5% | $411.9K | 2026-Q1 |
| QRG CAPITAL MANAGEMENT, INC. | ADD | 33,211 | 43,614 | +31.3% | $349.8K | 2026-Q1 |
| &PARTNERS | ADD | 22,485 | 32,717 | +45.5% | $262.2K | 2026-Q1 |
| PNC FINANCIAL SERVICES GROUP, INC. | ADD | 5,963 | 8,961 | +50.3% | $71.9K | 2026-Q1 |
| Rockefeller Capital Management L.P. | DOUBLED | 457 | 3,281 | +617.9% | $26.3K | 2026-Q1 |
| NATIONAL BANK OF CANADA /FI/ | TRIM | 1,650 | 1,130 | -31.5% | $9.0K | 2026-Q1 |
| CWM, LLC | NEAR_EXIT | 25,939 | 455 | -98.2% | $3.6K | 2026-Q1 |
| FIFTH THIRD BANCORP | DOUBLED | 114 | 346 | +203.5% | $2.8K | 2026-Q1 |
| ASSETMARK, INC | TRIM | 214 | 75 | -65.0% | $602.00 | 2026-Q1 |
| NORGES BANK | EXIT | 1,940,000 | 0 | -100.0% | $0.00 | 2026-Q1 |
| BANK OF MONTREAL /CAN/ | ADD | 3,013,723 | 4,394,750 | +45.8% | $41.1M | 2025-Q4 |
| NORGES BANK | NEW | — | 1,940,000 | — | $18.1M | 2025-Q4 |
| STATE STREET CORP | ADD | 374,822 | 628,274 | +67.6% | $5.9M | 2025-Q4 |
| ENVESTNET ASSET MANAGEMENT INC | TRIM | 515,853 | 346,605 | -32.8% | $3.2M | 2025-Q4 |
| Point72 Asset Management, L.P. | ADD | 147,700 | 277,406 | +87.8% | $2.6M | 2025-Q4 |
| FMR LLC | ADD | 64,126 | 93,500 | +45.8% | $874.2K | 2025-Q4 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
No SEC filing reports analyzed yet. Reports are generated when new filings are detected and processed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Dec 2025): 67% buy across 21 analysts — 5 strong buy, 9 buy, 5 hold, 2 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Dec 2025. No current recommendation available.
$10.87 mean target (Dec 2025)
$10.00 Low
$11.73 High
| Metric | Value |
|---|---|
| Current Price | $7.64 |
| Target Low | $10.00 |
| Target Mean | $10.87 |
| Target Median | $10.87 |
| Target High | $11.73 |
| # Analysts | 2 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.28 | $0.28 | $0.28 | 23.9% | +2.2% | 1↑ 0↓ | $2.0B | 3.2% | 1 |
| Next Q 2026-09-30 |
$0.29 | $0.29 | $0.29 | — | -3.4% | 0↑ 1↓ | $2.0B | 5.7% | 1 |
| Current FY 2026-12-31 |
$1.06 | $1.06 | $1.06 | 23.1% | -9.2% | 0↑ 1↓ | $7.7B | 2.1% | 1 |
| Next FY 2027-12-31 |
$1.44 | $1.34 | $1.55 | 36.0% | -0.8% | 0↑ 1↓ | $8.2B | 6.5% | 2 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.277 | |
| 7d ago | $0.271 | +0.006 |
| 30d ago | $0.271 | +0.006 |
| 60d ago | $0.000 | +0.277 |
| 90d ago | $0.000 | +0.277 |
8 analyst firms have rated this stock: 5 upgrades, 7 downgrades, 1 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Dec 8, 2025 | JP Morgan | MAINTAIN | Neutral | Neutral |
| Jun 17, 2025 | JP Morgan | MAINTAIN | Neutral | Neutral |
| Mar 12, 2024 | Deutsche Bank | DOWNGRADE | Hold | Sell |
| Dec 5, 2023 | JP Morgan | MAINTAIN | Neutral | Neutral |
| Nov 5, 2021 | Deutsche Bank | DOWNGRADE | Buy | Hold |
| Mar 23, 2021 | Credit Suisse | UPGRADE | Neutral | Outperform |
| Mar 11, 2021 | HSBC | UPGRADE | Hold | Buy |
| Oct 28, 2019 | Santander | UPGRADE | Hold | Buy |
| Jun 27, 2019 | JP Morgan | UPGRADE | Neutral | Overweight |
| Feb 8, 2019 | Berenberg | DOWNGRADE | Buy | Hold |
| Jan 2, 2019 | Morgan Stanley | MAINTAIN | Underweight | Underweight |
| Oct 1, 2018 | Morgan Stanley | MAINTAIN | Underweight | Underweight |
| Mar 1, 2018 | Morgan Stanley | MAINTAIN | Underweight | Underweight |
| Mar 17, 2016 | Nomura | INITIATE | — | Buy |
| Feb 9, 2016 | Berenberg | UPGRADE | Hold | Buy |
| Jan 4, 2016 | Morgan Stanley | DOWNGRADE | Equal-Weight | Underweight |
| Dec 2, 2015 | HSBC | DOWNGRADE | Buy | Hold |
| Nov 20, 2015 | Berenberg | DOWNGRADE | Buy | Hold |
| Feb 12, 2015 | Morgan Stanley | DOWNGRADE | Overweight | Equal-Weight |
| Mar 4, 2014 | JP Morgan | MAINTAIN | Neutral | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 5 | 9 | 5 | 2 | 0 | 67% | |
| May 1, 2026 | 5 | 9 | 5 | 2 | 0 | 67% | |
| Apr 1, 2026 | 5 | 9 | 5 | 2 | 0 | 67% | |
| Mar 1, 2026 | 5 | 10 | 4 | 2 | 0 | 71% | |
| Feb 1, 2026 | 5 | 10 | 4 | 2 | 0 | 71% | |
| Jan 1, 2026 | 3 | 11 | 4 | 2 | 0 | 70% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 20, 2026
Clinical Trial
Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD)
Phase Phase 3 — ACTIVE_NOT_RECRUITING
May 20, 2026
clinical_trial_readout
T-90d Trial Readout: Alpha-1 MP (Phase 3)
Trial: Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 An
May 11, 2026
clinical_trial_readout
T-90d Trial Readout: Alpha-1 MP (Phase 3)
Trial: Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 An
Mar 23, 2026
short_interest
FTD: GRFS — 109,843 shares ($0.8M) failed to deliver
Settlement: 20260323, Price: $7.58, FTD Value: $832,609.94, GRIFOLS S A SPON ADR REPSTG 1/
Mar 17, 2026
fda
Grifols Shares Results From its Chronos Platform Identifying Early Molecular Changes Associated with Parkinson’s Disease
<p align="justify">BARCELONA, Spain, March 17, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and l
Feb 11, 2026
short_interest
FTD: GRFS — 117,604 shares ($1.1M) failed to deliver
Settlement: 20260211, Price: $9.22, FTD Value: $1,084,308.88, GRIFOLS S A SPON ADR REPSTG 1/